Abstract
CD4+CD25+FOXP3+ T regulatory (Treg) cells are pivotal for the induction and maintenance of peripheral tolerance in both mice and humans. The possibility to use Treg cells for the treatment of T-cell-mediated diseases has recently gained increasing momentum. However, given the limited amount of circulating FOXP3+ Treg cells, efficient methods for their ex vivo expansion are highly desirable. Rapamycin allows for in vitro expansion of murine and human FOXP3+ Treg cells, which maintain their regulatory phenotype and suppressive capacity. Here, we describe in detail the powerful methods for enriching human FOXP3+ Treg cells starting from unfractionated CD4+ T cells or for expanding CD25+-enriched Treg cells in the presence of rapamycin.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Curotto de Lafaille, M. A., and J. J. Lafaille (2009) Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30, 626–635.
Wing, K., and S. Sakaguchi (2010) Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11, 7–13.
Malek, T. R., and I. Castro (2010) Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity. Immunity 33, 153–165.
Roncarolo, M. G., and M. Battaglia (2007) Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 7, 585–598.
Battaglia, M., A. Stabilini, and M. G. Roncarolo (2005) Rapamycin selectively expands CD4 + CD25 + FoxP3+ regulatory T cells. Blood 105, 4743–4748.
Battaglia, M., A. Stabilini, B. Migliavacca, J. Horejs-Hoeck, T. Kaupper, and M. G. Roncarolo (2006) Rapamycin promotes expansion of functional CD4 + CD25 + FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 177, 8338–8347.
Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. Basu S, Golovina T, Mikheeva T, June CH, Riley JL. J Immunol. 2008 May 1;180(9):5794–8.
Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells. Tresoldi E, Dell’albani I, Stabilini A, Jofra T, Valle A, Gagliani N, Bondanza A, Roncarolo MG, Battaglia M. Haematologica. 2011 Sep; 96(9):1357–65.
Acknowledgments
This work was supported by the Italian Telethon Foundation and the Juvenile Diabetes Research Foundation (GJT04014). This study was also supported in part by research funding from BD Biosciences.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Battaglia, M., Stabilini, A., Tresoldi, E. (2012). Expanding Human T Regulatory Cells with the mTOR-Inhibitor Rapamycin. In: Weichhart, T. (eds) mTOR. Methods in Molecular Biology, vol 821. Humana Press. https://doi.org/10.1007/978-1-61779-430-8_17
Download citation
DOI: https://doi.org/10.1007/978-1-61779-430-8_17
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-429-2
Online ISBN: 978-1-61779-430-8
eBook Packages: Springer Protocols